manifestations of systemic LE (SLE). The typical histopathologic pattern in CLE/SLE is interface dermatitis, which can also be observed in dermatomyositis (DM). While LE may affect any organ system, DM most commonly affect muscles and skin.

The aim of this study was to investigate the whole proteome of skin inflammatory foci in the cohort of CLE and DM patients in a comparative, hypothesis-free manner and identify disease-unique molecular mechanisms.

Methods CLE (n=6), DM (n=5) patients and controls (n=6) were recruited at diagnosis or disease exacerbation. Skin biopsies were acquired, examined by a pathologist and selected inflammatory foci were laser micro-dissected. The total protein content was analyzed by mass-spectrometry, further analysis was performed by string-db.org platform. Certain proteomic findings were confirmed by immunohistochemistry (IHC).

Results CLE infiltrates were more protein rich in comparison to DM lesions. There ratio of 5x upregulated proteins in LE/DM was 60, while ratio for DM/LE was 13. Our results confirmed high abundance of (IFN)-regulated proteins both in CLE and DM, including: IFIT1, IFIT2, IFIT3, MX1, MX2, OAS2, OAS3, STAT1, STAT2, DDX58, DDx60 and EIF2AK2. Proteins expressed differentially in CLE covered complement proteins (C1b), including membrane attack complex (MAC) (C5, C6, C7, C8A and B) and complement regulators (CFHR1, CFHR2, CFHR5), as well as regulators of coagulation: thrombospondin 2 (THBS2), thrombin (F2), fibrinogen (F12) and annexin A3 (ANXA3). Importantly, we identified interleukin (IL) -16 as the only detectable and highly abundant cytokine in the CLE lesions and confirmed this finding by IHC.

Conclusions Our data confirm evidence on IFN-regulated processes in CLE/SLE. Importantly, we identified IL-16 as a novel cytokine most strongly upregulated locally in the skin lesions. Moreover, we identified activation of MAC, complement regulating proteins as well as involvement of coagulation/fibrinolysis system. The study brings information on novel pathways involved in the inflammatory foci of the skin lesions in CLE patients. Our findings are of interest in further search of new therapeutic targets.

Abstract 033 Figure 1

Methods Forty-two patients with an incident biopsy-proven active proliferative (class III/IV ± V) LN from the LN database of the Université catholique de Louvain were included in the present retrospective study. Per-protocol repeat kidney biopsies were performed in all patients after a median time of 24.3 (IQR: 21.3–26.2) months. The NIH activity index (AI) and chronicity index (CI) scores were assessed in both baseline and repeat biopsies.

Results Despite a moderate correlation between urinary protein/creatinine (U-P/C) ratios and AI scores at repeat biopsy (r=0.48; P=0.001), ten patients (23.8%) with U-P/C ratios <1.0 g/g still had a high degree of histological activity (AI score >3; figure 1). High AI scores in repeat biopsies were associated with an increased probability and/or shorter time to renal relapse (N=11) following the repeat biopsy (HR: 1.2; 95% CI: 1.1–1.3; P=0.007), independently of proteinuria levels. High NIH CI scores in repeat biopsies were associated with a sustained increase in serum creatinine levels corresponding to ≥120% of the baseline value (HR: 1.8; 95% CI: 1.1–2.9; P=0.016) through a median follow-up time of 131.5 (IQR: 73.8–178.2) months. Baseline AI/CI scores were not predictive of these outcomes.

Abstract 034

VARIANTS IN BANK1 ARE ASSOCIATED WITH LUPUS NEPHRITIS

Karin Bolin, Dog Leonard, Johanna K Sandling, Andrei Alexsson, Pascal Pucholt, Malena Loberg Haahrus, Joanne Nithitham, Andreas Jörsen, Christopher Sjöwall, Anders A Bengtsson, Solbritt Rantapää-Dahlberg, Elisabet Svenungsong, Iva Gumnarsson, Ann- Christina Syvänen, Karoline Larng, Anne Troldborg, Anne Voss, Olov Olsson, Sören Jacobsen, Lindsey Criswell, Karoline Lerang, Anne Troldborg, Anne Voss, Olov Olsson, Sören Jacobsen, Lindsey Criswell, Karoline Lerang, Anne Troldborg, Anne Voss, Olov Olsson, Sören Jacobsen, Lindsey Criswell, Karoline Lerang, Anne Troldborg, Anne Voss, Olov Olsson, Sören Jacobsen, Lindsey Criswell, Karoline Lerang, Anne Troldborg, Anne Voss, Olov Olsson, Sören Jacobsen, Lindsey Criswell, Karoline Lerang, Anne Troldborg, Anne Voss, Olov Olsson, Sören Jacobsen, Lindsey Criswell, Karoline Lerang, Anne Troldborg, Anne Voss, Olov Olsson, Sören Jacobsen, Lindsey Criswell, Karoline Lerang, Anne Troldborg, Anne Voss, Olov Olsson, Sören Jacobsen, Lindsey Criswell, Karoline Lerang, Anne Troldborg, Anne Voss, Olov Olsson, Sören Jacobsen, Lindsey Criswell, Karoline Lerang, Anne Troldborg, Anne Voss, Olov Olsson, Sören Jacobsen, Lindsey Criswell, Karoline Lerang, Anne Troldborg, Anne Voss, Olov Olsson, Sören Jacobsen, Lindsey Criswell, Karoline Lerang, Anne Troldborg, Anne Voss, Olov Olsson, Sören Jacobsen, Lindsey Criswell, Karoline Lerang, Anne Troldborg, Anne Voss, Olov Olsson, Sören Jacobsen, Lindsey Criswell, Karoline Lerang, Anne Troldborg, Anne Voss, Olov Olsson, Sören Jacobsen, Lindsey Criswell, Karoline Lerang, Anne Troldborg, Anne Voss, Olov Olsson, Sören Jacobsen, Lindsey Criswell, Karoline Lerang, Anne Troldborg, Anne Voss, Olov Olsson, Sören Jacobsen, Lindsey Criswell, Karoline Lerang, Anne Troldborg, Anne Voss, Olov Olsson, Sören Jacobsen, Lindsey Criswell, Karoline Lerang, Anne Troldborg, Anne Vos...